A detailed history of Brown, Lisle/Cummings, Inc. transactions in Viatris Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,879 shares of VTRS stock, worth $24,427. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,879
Previous 1,183 58.83%
Holding current value
$24,427
Previous $12.6 Million 73.48%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$10.32 - $12.13 $7,182 - $8,442
696 Added 58.83%
1,879 $21.8 Million
Q2 2024

Jul 17, 2024

SELL
$10.05 - $12.02 $18,592 - $22,237
-1,850 Reduced 61.0%
1,183 $12.6 Million
Q1 2024

Jun 28, 2024

BUY
$11.27 - $13.53 $11,067 - $13,286
982 Added 47.88%
3,033 $36.2 Million
Q4 2023

Jun 28, 2024

SELL
$8.77 - $10.85 $30,002 - $37,117
-3,421 Reduced 62.52%
2,051 $22.2 Million
Q3 2023

Jun 28, 2024

SELL
$9.59 - $11.35 $44,957 - $53,208
-4,688 Reduced 46.14%
5,472 $54 Million
Q2 2023

Jun 28, 2024

SELL
$9.02 - $10.29 $9,020 - $10,290
-1,000 Reduced 8.96%
10,160 $101 Million
Q1 2023

Jun 28, 2024

SELL
$9.2 - $12.26 $9,200 - $12,260
-1,000 Reduced 8.22%
11,160 $107 Million
Q4 2022

Jun 28, 2024

BUY
$8.72 - $11.56 $2,528 - $3,352
290 Added 2.44%
12,160 $135 Million
Q3 2022

Jun 28, 2024

SELL
$8.48 - $11.13 $6,410 - $8,414
-756 Reduced 5.99%
11,870 $101 Million
Q2 2022

Jun 28, 2024

SELL
$9.95 - $12.27 $25,133 - $30,994
-2,526 Reduced 16.67%
12,626 $132 Million
Q1 2022

Jun 28, 2024

BUY
$9.81 - $15.4 $32,000 - $50,234
3,262 Added 27.43%
15,152 $165 Million
Q4 2021

Jun 28, 2024

BUY
$12.09 - $14.68 $143,750 - $174,545
11,890 New
11,890 $161 Million

Others Institutions Holding VTRS

About Viatris Inc


  • Ticker VTRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,212,669,952
  • Market Cap $15.8B
  • Description
  • Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...
More about VTRS
Track This Portfolio

Track Brown, Lisle/Cummings, Inc. Portfolio

Follow Brown, Lisle/Cummings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.